Skip to main content

arGEN-X

argenx SE, operating legally as argenx NV, is an international biotechnology company focused on developing antibody-based therapies for autoimmune diseases and cancer. The company utilizes its proprietary SIMPLE Antibody platform to discover and commercialize human monoclonal antibody treatments. Its primary revenue driver is global sales of Vyvgart (efgartigimod), an approved neonatal Fc receptor blocker used to treat generalized myasthenia gravis and related autoimmune conditions. End markets primarily comprise specialized hospital networks, neurology clinics, and immunology medical practices across North America, Europe, and Asia-Pacific. argenx occupies a leading commercial position among commercial-stage European biotechnology firms specializing in rare autoimmune disorders. The company maintains operational headquarters in Ghent, Belgium, and legal domicile in the Netherlands, with listings on Euronext Brussels and the Nasdaq under the ticker symbol ARGX.

46 of the funds FundTelligence covers report a position in arGEN-X.

Legal name
arGEN-X N.V.
Sector
Health Care
Country
Belgium
Funds holding it
46

Funds holding arGEN-X

Showing the 8 largest of 46 funds holding it.

Loading...